Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 6/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.39 |
| ▸ | NOS3 | P29474 | 5/20 | 0.36 |
| ▸ | NOS1 | P29475 | 2/20 | 0.32 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24140212 | 0.83 | TDP1 (0.33) | — | |
| SCHEMBL15889710 | 0.78 | NOS2 (0.39) | NOS2TLR8NOS3NOS1 | |
| SCHEMBL25101391 | 0.73 | TDP1 (0.32) | TLR8 | |
| SCHEMBL24375650 | 0.72 | LRRK2 (0.37) | NOS2NOS1 | |
| SCHEMBL31097846 | 0.71 | NOS2 (0.39) | NOS2NOS3NOS1 | |
| SCHEMBL20088854 | 0.71 | NOS2 (0.39) | NOS2NOS3NOS1 | |
| SCHEMBL19413025 | 0.69 | NOS2 (0.35) | NOS2TLR8NOS3 | |
| SCHEMBL25101446 | 0.68 | TDP1 (0.40) | — | |
| SCHEMBL21649191 | 0.68 | LOXL2 (0.44) | — | |
| SCHEMBL8134172 | 0.67 | NOS2 (0.47) | NOS2TLR8NOS3NOS1PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11673901-B2 | Polycyclic compounds as allosteric SHP2 inhibitors | Revolution Medicines, Inc. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20200407372-A1 | POLYCYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11673901-B2 | Polycyclic compounds as allosteric SHP2 inhibitors | PTPN18, PTPN1, PTPRJ | NOS2 4606/4885TLR8 845/4885NOS3 4632/4885 |
| US-20200407372-A1 | POLYCYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | PTPN18, PTPN1, PTPRJ | NOS2 4606/4885TLR8 845/4885NOS3 4632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.